“And over the next few years, expect many of these programs to advance to Phase two and to become visible to you.”

In context

“have resulted in an expanded late-phase pipeline comprising programs having potential commercial opportunity of over $50 billion by the mid-2030s. Wind rebar and CapVaxin represent the initial launches from this robust pipeline of 20 promising potential new growth drivers we expect to come to the market over the next few years almost all of which have blockbuster potential. Looking ahead, we have a rich slate of data readouts presentations, filings, and additional approvals. Our pipeline includes some of the world's most scientifically advanced modalities and Dean and our research colleagues are advancing several molecules that have foundational multi-indication potential in areas of significant unmet need. We've also deepened and extended our commitment to early research and development. And over the next few years, expect many of these programs to advance to Phase two and to become visible to you. Thanks to the incredible efforts of our dedicated team and the strong progress we are achieving, we believe that we're well-positioned to successfully navigate through the KEYTRUDA LOE period. And our work is not finished. Science and value-driven business development remains a top priority. And we continue to assess opportunities with urgency, and an eye toward driving near and long-term growth and value creation. In summary, our results reflect the continued demand for breakthrough therapies and novel solutions that can address global health challenges. We're leveraging our scientific leadership to deliver the next wave of innovation that can save and improve lives around the world. Our commercial performance today continues to enable the advancement of our pipeline and in turn create l”